公开(公告)号：US10550102B2

公开(公告)日：2020-02-04

申请号：US16216420

申请日：2018-12-11

Applicant: NOVARTIS AG

Inventor： Christopher M. Adams ,  Doug Bevan ,  Michael Paul Capparelli ,  Takeru Ehara ,  Luciana Ferrara ,  Nan Ji ,  Erik Meredith ,  Muneto Mogi ,  James J. Powers ,  Ganesh Prasanna ,  Nello Mainolfi ,  Mitsunori Kato

IPC: C07D401/14 ,  C07D413/14 ,  C07D401/10 ,  C07D401/12 ,  A61K9/00 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  C07D405/14 ,  C07D401/04

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US11845730B2

公开(公告)日：2023-12-19

申请号：US17656313

申请日：2022-03-24

Applicant: Novartis AG

Inventor： Donglei Liu ,  Julien Papillon ,  Stefan Peukert ,  James J. Powers

IPC: C07D217/02 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12

CPC classification number: C07D217/02 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12

Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.